#USA #Marlborough #Boston Scientific #COO #Joseph Fitzgerald

Boston Scientific Welcomes Joseph M. Fitzgerald as New COO

In a significant leadership shift, Boston Scientific Corporation (NYSE: BSX) has announced the appointment of Joseph M. Fitzgerald as the Executive Vice President and Chief Operating Officer (COO), effective January 1, 2027. This strategic move highlights the company's commitment to enhancing its operational capabilities and aligning its growth strategies with the evolving healthcare landscape.

A Vision for Enhanced Operations

Effective immediately, Fitzgerald will oversee the global operations of Boston Scientific, which is renowned for its innovative medical technologies. This transition comes along with the establishment of a revised operational structure comprising three key reportable segments: Interventional Therapies, Rhythm Solutions, and MedSurg. These changes aim to bolster efficiency and facilitate swift decision-making, ensuring the company is well-positioned to respond to market demands and customer needs.

Mike Mahoney, the Chairman and CEO of Boston Scientific, expressed confidence in Fitzgerald’s capabilities, emphasizing his deep understanding of the company’s business model and market dynamics. Mahoney noted, “Joe's deep knowledge of our business and markets, strategic leadership, and proven track record of execution make him well suited for this role. These adjustments reflect the scale and breadth of our operations and the opportunities ahead.”

Outline of the New Segments

As part of this reorganization, the new operational segments will be defined as follows:

• - Interventional Therapies: This will encompass the Interventional Cardiology, Vascular Therapies, and Interventional Oncology Embolization businesses.
• - Rhythm Solutions: This segment includes Electrophysiology, the WATCHMAN product line, and Cardiac Rhythm Management Diagnostics.
• - MedSurg: This will consist of divisions focused on Endoscopy, Urology, and Neuromodulation.

Each of these segments will report directly to Fitzgerald, with seasoned executives leading them. Highlighting the company's focus on innovation, the newly structured segments are expected to enhance strategic resource allocation across the portfolio, further driving the company’s growth and market penetration.

Background and Experience

Before this appointment, Fitzgerald held the position of Executive Vice President and Group President of Cardiovascular at Boston Scientific. His leadership has been instrumental in strengthening the company’s portfolio, characterized by an emphasis on organic innovation and strategic investments. Under his stewardship, Boston Scientific has successfully introduced new technologies that have significantly improved patient care worldwide.

Fitzgerald's career trajectory within Boston Scientific exemplifies the company's commitment to internal talent development and reinvention. His extensive experience in the medical technology sector positions him well as he steps into this new role, facing both the current challenges and future opportunities in healthcare.

Looking Ahead

With Joseph M. Fitzgerald at the helm as COO, Boston Scientific is set to enhance its operational efficiency amid a rapidly changing medical landscape. The company aims to establish a more adaptable framework to address the diverse and evolving healthcare needs of patients globally. By streamlining its operations, Boston Scientific aspires to remain closely connected to its customers and the patients they serve, strengthening its position as a leader in the medical technology sector.

Boston Scientific has a proud history of transforming lives through innovative medical solutions and is committed to advancing science for life. As they move forward with this new leadership structure, the company's strategic initiatives will undoubtedly shape the future of medical technology and patient care across the globe.